Iron metabolism and malaria

Andrew M Prentice1, Hala Ghattas, Conor Doherty

  • 1MRC International Nutrition Group, London School of Hygiene and Tropical Medicine, London 1IE 7HT, United Kingdom. Andrew.prentice@lshtm.ac.uk

Food and Nutrition Bulletin
|February 27, 2008
PubMed

Insights

Iron supplementation in children in malaria-prone regions may increase malaria incidence without prophylaxis. Targeted iron for anemia or use with malaria prevention is safer.

Area of Science:

  • Pediatric infectious diseases
  • Nutritional science
  • Immunology

Background:

  • Recent trials suggest universal iron administration in malaria-endemic areas correlates with adverse health outcomes in children.
  • Host-pathogen interactions involving iron metabolism are crucial in understanding this relationship.

Purpose of the Study:

  • To review ecologic and intervention studies on iron and malaria in children.
  • To analyze the biological mechanisms of iron metabolism in host-pathogen interactions.
  • To provide evidence-based recommendations for iron supplementation in malarious regions.

Main Methods:

  • Literature review of ecologic and intervention trials.
  • Analysis of existing data on host-pathogen interactions and iron metabolism.
  • Synthesis of evidence regarding iron supplementation and malaria incidence.

Main Results:

  • The balance of evidence indicates that iron (often with folic acid) increases malaria incidence when given without prophylaxis or prompt treatment.
  • Detrimental effects of iron may be modulated by baseline iron status, hemoglobinopathies, G6PD deficiency, and host genetic factors like haptoglobin variants.
  • Malaria-induced anemia is primarily due to iron maldistribution and suppressed erythropoiesis, not gross iron deficiency.

Conclusions:

  • Universal iron supplementation in malarious areas should be coupled with prophylaxis (e.g., intermittent preventive therapy) or robust healthcare services for diagnosis and treatment.
  • Targeted iron supplementation for anemic children is a potential alternative approach.
  • Iron supplementation should be withheld during malaria treatment to avoid inhibiting efficacy and absorption.

Related Concept Videos

Malaria01:29

Malaria

Malaria pathogenesis in humans reflects a delicate interplay between parasite biology and host response. Clinical illness reflects a host’s immune response to the parasite’s asexual replication cycle, which is often asymptomatic in individuals with partial immunity. From the parasite's perspective, transmission between mosquito and human with minimal host pathology is evolutionarily advantageous. Among the six Plasmodium species infecting humans, P. falciparum and P. vivax dominate in global...
Microbes and Other Elemental Cycles01:24

Microbes and Other Elemental Cycles

Microbial activity plays a pivotal role in the biogeochemical cycling of iron and manganese, especially at the redox gradients characteristic of stratified aquatic environments. These cycles are driven by microbial transformations between oxidized and reduced forms of the metals, allowing organisms to exploit them for metabolic energy and structural purposes.Iron Cycling Across Redox GradientsIn neutral, oxygen-rich surface waters, iron is predominantly found in its oxidized, insoluble ferric...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
The Electron Transport Chain01:30

The Electron Transport Chain

The electron transport chain or oxidative phosphorylation is an exothermic process in which free energy released during electron transfer reactions is coupled to ATP synthesis. This process is a significant source of energy in aerobic cells, and therefore inhibitors of the electron transport chain can be detrimental to the cell's metabolic processes.
Inhibitors of the electron transport chain
Rotenone, a widely used pesticide, prevents electron transfer from Fe-S cluster to ubiquinone or Q in...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...